化疗联合吉非替尼小分子靶向治疗肺癌的疗效及安全性  

Curative effects and safety of chemotherapy combined with small molecular target therapy with gefitinib in treatment of lung cancer

作　　者：李直苹 周瑜[1] LI Zhiping;ZHOU Yu(Second Department of Pulmonary Disease,Jiangjin District Hospital of Traditional Chinese Medicine,Chongqing 402260,China)

机构地区：[1]重庆市江津区中医院肺病二科

出　　处：《中国医药科学》2019年第20期201-203,共3页China Medicine And Pharmacy

摘　　要：目的探讨肺癌采取化疗联合吉非替尼小分子靶向治疗的疗效。方法选取2015年5月~2018年11月我院接收的50例肺癌患者,随机分为对照组(n=25,采取常规化疗)与观察组(n=25,采取化疗联合吉非替尼治疗),对疗效及安全性进行观察。结果观察组疾病缓解率较对照组明显要高,差异有统计学意义(P<0.05);治疗前,两组患者血清肿瘤标志物比较差异无统计学意义(P>0.05),治疗后,观察组各项血清肿瘤标志物均较对照组明显要低,差异有统计学意义(P<0.05);两组患者治疗期间均有食欲下降、白细胞减少、腹泻、皮疹等不良反应发生,但两组比较差异无统计学意义(P>0.05)。结论对肺癌患者采取化疗联合吉非替尼治疗,能有效提高疗效,不良反应少,值得于临床广泛推广。Objective To explore the curative effects of chemotherapy combined with small molecular target therapy with gefitinib in treatment of lung cancer.Methods 50 patients with lung cancer who were admitted to our hospital from May 2015 to November 2018 were selected.They were randomly divided into the control group(n=25,routine chemotherapy)and the observation group(n=25,chemotherapy combined with gefitinib).Curative effects and safety were observed.Results The disease remission rate in the observation group was significantly higher than expected(P<0.05),and the difference was statistically significant.Before treatment,there was no significant difference in serum tumor markers between the two groups(P>0.05).The difference was not statistically significant.After treatment,the serum tumor markers in the observation group were significantly lower than the control group(P<0.05),and the difference was statistically significant.Both groups had adverse reactions such as decreased appetite,leukopenia,diarrhea,and rash during treatment,but there was no significant difference between the two groups(P>0.05).The difference was not statistically significant.Conclusion Chemotherapy andgefitinib in treatment of patients with lung cancercan increase the curative effect and reduce the adverse reactions.It is worthy of wide promotion in clinical practice.

关 键 词：肺癌 靶向治疗 吉非替尼 化疗 

分 类 号：R734.2[医药卫生—肿瘤]